Head-to-head · WeighScore
Aurelius Health Group vs Enhance MD
By GLP-1 ScorecardUpdated
Score comparison
Enhance MD has the higher recorded score — 84.8/100 to 60.8/100.
Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Enhance MD pairs compounded injections with advertised lab testing and care; its four-week supply and 48-week longer plan require a different budget from calendar-month pricing.
Before you choose
Aurelius Health Group does not publish a semaglutide price, so its Aurelius Health Group review sets out what it does disclose, while the Enhance MD review explains the conditions attached to Enhance MD's figure. The semaglutide cost page compares published rates across the field. Ask Aurelius Health Group for a written total before treating either one as the cheaper choice.
If neither one fits, Aurelius Health Group vs Invigor Medical and AVArx vs Enhance MD compare each of them with another graded program, and the list of alternatives to Aurelius Health Group ranks the programs closest to Aurelius Health Group on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the GoodLife Health review covers one graded close to these two, at 69.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Aurelius Health Group | Enhance MD |
|---|---|---|
| WeighScore | 60.8/100 | 84.8/100 |
| Grade | C | B |
| Site position | #340 | #14 |
| Semaglutide | No separate semaglutide price published | $249 every 4 weeks on the shortest Core plan; from $212 per 4-week equivalent on a 48-week billed plan (confirm first-order promotion and charge) |
| Tirzepatide | No separate tirzepatide price published | $329 every 4 weeks on the shortest Advanced plan; from $280 per 4-week equivalent on a 48-week billed plan (confirm first-order promotion and charge) |
| Coverage | Confirm program availability in your state | FAQ lists 40 states plus DC, subject to product availability; confirm treatment, clinician and pharmacy for your address |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Publishes the introductory and recurring program prices
- Lists consultations and ongoing monitoring as part of the program
- Publishes a cancellation cutoff before the next bill
What to consider
- The public price does not identify the selected prescription and usable supply
- Cancellation notice is due at least 72 hours before the next bill
- The summary and detailed policy differ on the scope of medical-disqualification refunds
Site position #14 · B
Strengths
- Core and Advanced publish separate short- and longer-plan prices with billing periods stated
- Product pages advertise care, coaching, supplies and six-month labs; baseline labs are described in onboarding
- Terms identify independent medical groups and possible pharmacies rather than only a generic provider network
- The FAQ publishes a product-availability state list and a clinical-ineligibility initial-payment refund policy
What to consider
- Four-week billing and a 48-week longer plan are not twelve calendar-month payments
- First-order discounts differ by term; actual debit, dose, quantity and ongoing schedule require confirmation
- An unused-prepaid-balance refund formula and precise refill cancellation cutoff were not established
- Pharmacy lists differ across public documents; the assigned dispenser and prescriber remain unknown
- One disclosed pharmacy has a closed Oklahoma nonresident permit; this limited finding does not establish company closure or the pharmacy assigned to a patient
- Elite combination and microdose benefit claims were not independently established; no branded or oral GLP-1 offer was established in the reviewed menu
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.